Janus kinase inhibitors in dermatology: Part II. A comprehensive review
Recommended Citation
Chapman S, Gold LS, and Lim HW. Janus kinase inhibitors in dermatology: Part II. A comprehensive review. J Am Acad Dermatol 2021.
Document Type
Article
Publication Date
7-3-2021
Publication Title
Journal of the American Academy of Dermatology
Abstract
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is implicated in the pathogenesis of a number of inflammatory dermatoses. Clinical trials and other studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here we review JAK inhibitors currently under investigation for the treatment of alopecia areata, vitiligo, sarcoidosis, necrobiosis lipoidica, granuloma annulare, and systemic lupus erythematosus with a special emphasis on safety and the implications of JAK inhibitors during the novel coronavirus 2019 pandemic.
PubMed ID
34228996
ePublication
ePub ahead of print
